Quoin pharmaceuticals announces positive interim data from two ongoing netherton syndrome clinical studies

Ashburn, va., dec. 18, 2024 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical data from two of its ongoing netherton syndrome clinical studies.
QNRX Ratings Summary
QNRX Quant Ranking